BRIEF published on 09/18/2024 at 07:05, 6 months 22 days ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 6 months 22 days ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 7 months 8 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 7 months 8 days ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 7 months 11 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 7 months 11 days ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 8 months 5 days ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 8 months 5 days ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 9 months 13 days ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 9 months 13 days ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 04/11/2025 at 02:40, 3 hours 42 minutes ago McFarlane Lake Announces Closing of Final Tranche of Upsized $1.3 Million Private Placement Offering
Published on 04/11/2025 at 02:00, 4 hours 22 minutes ago Battery X Metals Announces Formation of Critical Battery Metals Exploration Subsidiary and Expansion of Quebec Exploration Portfolio with Acquisition of 39 Additional Mineral Claims
Published on 04/11/2025 at 00:00, 6 hours 22 minutes ago Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Published on 04/10/2025 at 23:00, 7 hours 22 minutes ago Highlander Silver Receives Conditional Approval to List on the TSX, Files Base Shelf Prospectus and Establishes ATM Program as Longer Term Financial Alternatives
Published on 04/11/2025 at 06:00, 22 minutes ago Sales for the first quarter 2025 Ad hoc announcement pursuant to Art. 53 LR
Published on 04/11/2025 at 05:00, 1 hour 22 minutes ago LISA with Leading Thai and International Artists Captivate the World at the Amazing Thailand Countdown 2025, Reinforcing ICONSIAM as the Ultimate Global Countdown Destination
Published on 04/10/2025 at 20:47, 9 hours 35 minutes ago EQS-Adhoc: Hinkel & Cie. GmbH: first creditors´meeting of the bond DE000A2AAPX4
Published on 04/10/2025 at 20:44, 9 hours 38 minutes ago EQS-Adhoc: artnet AG: artnet is in talks with two investors regarding a potential takeover offer
Published on 04/10/2025 at 19:00, 11 hours 22 minutes ago Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Published on 04/10/2025 at 17:45, 12 hours 37 minutes ago EURAZEO INVESTS IN EKOSCAN INTEGRITY, A LEADING GLOBAL PROVIDER OF ADVANCED NON-DESTRUCTIVE TESTING SOLUTIONS FOR CRITICAL INDUSTRIAL APPLICATIONS AND INFRASTRUCTURE
Published on 04/09/2025 at 18:59, 1 day 11 hours ago Description of the 2025-2026 Share Buyback Program
Published on 04/09/2025 at 18:57, 1 day 11 hours ago Minutes of the Combined General Meeting held on April 9, 2025
Published on 04/09/2025 at 17:45, 1 day 12 hours ago COGELEC : 2024 full-year results and Q1 2025 revenue.
